Modulation of translation factor's gene expression by histone deacetylase inhibitors in breast cancer cells

References

1 Villar-Garea A, Esteller M. Histone deacetylase inhibitors: understanding a new wave of anticancer agents. Int J Cancer 2004; 112: 171–8. 10.1002/ijc.20372Search in Google Scholar

2 Somech R, Izraeli S, Simon AJ. Histone deacetylase inhibitors – a new tool to treat cancer. Cancer Treat Rev 2004; 30: 461–72. 10.1016/j.ctrv.2004.04.006Search in Google Scholar

3 Davis T, Kennedy C, Chiew Y, Clarke C, DeFazio A. Histone deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression in normal mammary epithelial cells. Clin Cancer Res 2000; 6: 4334–42. Search in Google Scholar

4 Fagot D, Buquest-Fagot C, Lallemand F, Mester J. Anti-proliferative effects of sodium butyrate in adriamycinsensitive and -resistant human cancer cell lines. AntiCancer Drugs 1994; 5: 548–56. 10.1097/00001813-199410000-00006Search in Google Scholar

5 Velazquez OC, Zhou D, Seto RW, Jabbar A, Choi J, Lederer HM, Rombeau JL. In vivo crypt surface hyperproliferation is decreased by butyrate and increased by deoxycholate in normal rat colon: associated in vivo effects on c-Fos and c-Jun expression. Parenter Enteral Nutr 1996; 20: 243–50. 10.1177/0148607196020004243Search in Google Scholar

6 Terao Y, Nishida J, Horiuchi S, Rong F, Ueoka Y, Matsuda T, et al. Sodium butyrate induces growth arrest and senescence-like phenotypes in gynecologic cancer cells. Int J Cancer 2001; 94: 257–67. 10.1002/ijc.1448Search in Google Scholar

7 Kuefer R, Hofer M, Altug V, Zorn C, Genze F, Kunzi-Rapp K, et al. Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer. Br J Cancer 2004; 90: 535–41. 10.1038/sj.bjc.6601510Search in Google Scholar

8 Boffa L, Vidali G, Mann, S, Allfrey V. Suppression of histone deacetylation in vivo and in vitro by sodium butyrate. J Biol Chem 1978; 253: 3364–6. 10.1016/S0021-9258(17)34804-4Search in Google Scholar

9 Chopin V, Toillon R, Jouy N, Le Bourhis X, P21 WAF/CIPI is dispensable for G1 arrest, but indispensable for apoptosis induced by sodium butyrate in MCF-7 breast cancer cells. Oncagene 2004; 23: 21–9. 10.1038/sj.onc.1207020Search in Google Scholar PubMed

10 Suenaga M, Soda H, Oka M, Yamaguchi A, Nakatomi K, Shiozawa K, et al. Histone deacetylase inhibitors suppress telomerase reverse transcriptase mRNA expression in prostate cancer cells. Int J Cancer 2002; 97: 621–5. 10.1002/ijc.10082Search in Google Scholar PubMed

11 Gilbert J, Baker S, Bowling M, Grochow L, Figg W, Zabelina Y, et al. A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res 2001; 7: 2292–300. Search in Google Scholar

12 Coradini D, Biffi A, Costa A, Pellizaro C, Pirronello E, Fronzo G. Effect of sodium butyrate on human breast cancer cell lines. Cell Prolif 1997; 30: 149–59. 10.1111/j.1365-2184.1997.tb00931.xSearch in Google Scholar

13 Louis M, Rosato R, Brault L, Osbild S, Battaglia E, Yang X, et al. The histone deacetylase inhibitor sodium butyrate induces breast cancer cell apoptosis through diverse cytotoxic actions including glutathione depletion and oxidative stress. Int J Oncol 2004; 25: 1701-11. 10.3892/ijo.25.6.1701Search in Google Scholar

14 Chopin V, Toillon R, Jouy N, Le Bourhis X. Sodium butyrate induces P53-independent, Fas-mediated apoptosis in MCF-7 human breast cancer cells. Br J Pharmacol 2002; 135: 79–86. 10.1038/sj.bjp.0704456Search in Google Scholar

15 Yoshida M, Furumai R, Nishiyama M, Komatsu Y, Ni-shino N, Horinouchi S. Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother Pharmacol 2001; 48(Suppl 1): S20–6. 10.1007/s002800100300Search in Google Scholar

16 Strait K, Dabbas B, Hammond E, Warnick C, Ilstrup S, Ford C. Cell cycle blockade and differentiation of ovarian cancer cells by the histone deacetylase inhibitor trichostatin A are associated with changes in p21, Rb, and Id proteins. Mol Cancer Ther 2002; 1: 1181–90. Search in Google Scholar

17 Suzuki T, Yokozaki, Kuniyasu H, Hayashi K, Naka K, Ono S, et al. Effect of trichostatin A on cell growth and expression of cell cycle- and apoptosis-related molecules in human gastric and oral carcinoma cell lines. Int J Cancer 2000; 88: 992–7. 10.1002/1097-0215(20001215)88:6<992::AID-IJC24>3.0.CO;2-9Search in Google Scholar

18 Blagosklonny M, Robey R, Sackett D, Du L, Traganos F, Darzynkiewicz Z, et al. Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol Cancer Ther 2002; 1: 937–41. Search in Google Scholar

19 Vigushin D, Ali S, Pace P, Mirsaidi N, Ito K, Adcock I, et al. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res 2001; 7: 971–6. Search in Google Scholar

20 Thornson S, Anand N, Purcell D, Lee J. Not just for housekeeping: protein initiation and elongation factors in cell growth and tumorigenesis. J Mol Med 2003; 81: 536–48. 10.1007/s00109-003-0461-8Search in Google Scholar

21 Abbot C, Proud C. Translation factors: in sickness and in health. Trends Biochem Sci 2004; 29: 25–31. 10.1016/j.tibs.2003.11.006Search in Google Scholar

22 Joseph P, O'Kernick C, Othumpangat S, Lei Y, Yuan B, Ong T. Expression profile of eukaryotic translation factors in human cancer tissues and cell lines. Mol Carcinog 2004; 40: 171–9. 10.1002/mc.20033Search in Google Scholar

23 Ejiri S. Moonlighting functions of polypeptide elongation factor 1: from actin bundling to zinc finger protein R1-associated nuclear localization. Biosci Biotechnol Biochem 2002; 66: 1–21. 10.1271/bbb.66.1Search in Google Scholar

24 Bischoff C, Kahns S, Lund A, Jørgensen H, Præstegaard M, Clark B, et al. The human elongation factor 1 A-2 gene (EEF1A2): complete sequence and characterization of gene structure and promoter activity. Genomics 2000; 68: 63–70. 10.1006/geno.2000.6271Search in Google Scholar

25 Anand N, Murthy S, Amann G, Wernick M, Porter L, Cukier H, et al. Gene encoding protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer. Nat Genet 2002; 31: 301–5. 10.1038/ng904Search in Google Scholar

26 Lee J. The role of protein elongation factor eEF1A2 in ovarian cancer. Reprod Biol Endocrinol 2003; 1: 69. 10.1186/1477-7827-1-69Search in Google Scholar

27 Zhouravleva G, Frolova L, Le Goff X, Le Guellec R, Inge-Vechtomov S, Kisselev L, et al. Termination of translation in eukaryotes is governed by two interacting polypeptide chain release factors, eRF1 and eRF3. EMBO J 1995; 14: 4065–72. 10.1002/j.1460-2075.1995.tb00078.xSearch in Google Scholar

28 Frolova L, Le Goff X, Zhouravleva G, Davydova E, Philippe M, Kisselev L. Eukaryotic polypeptide chain release factor eRF3 is an eRF1- and ribosome-dependent guanosine triphosphatase. RNA 1996; 2: 334–41. Search in Google Scholar

29 Jakobsen C, Søgaard M, Jean-Jean O, Frolova L, Justesen J. Identification of eRF3b, a human polypeptide chain release factor with eRF3 activity in vitro and in vivo. Mol Biol 2001; 35: 575–83. 10.1023/A:1010527127440Search in Google Scholar

30 Hoshino S, Hosoda N, Araki Y, Kobayashi T, Uchida N, Fumakoshi Y, et al. Novel function of the eukaryotic polypeptide-chain releasing factor 3 (eRF3/GSPT) in the mRNA degradation pathway. Biochemistry (Mosc) 1999; 64: 1621–27. Search in Google Scholar

31 Uchida N, Hoshino S, Imataka H, Sonenberg N. A novel role of the mammalian GSPT/eRF3 associating with poly(A)-binding protein in Cap-Poly(A)-dependent translation. J Biol Chem 2002; 277: 50286–92. 10.1074/jbc.M203029200Search in Google Scholar

32 Cosson B, Berkova N, Couturier A, Chabelskaya S, Philippe M, Zhouravleva G. Poly(A)-binding protein and eRF3 are associated in vivo in human and Xenopus cells. Biol Cell 2002; 94: 205–16. 10.1016/S0248-4900(02)01194-2Search in Google Scholar

33 Hosoda N, Kobayashi T, Uchida N, Funakoshi Y, Kikuchi Y, Hoshino S, et al. Translation termination factor eRF3 mediates mRNA decay trough the regulation of deadenylation. J Biol Chem 2003; 278: 38287–91. 10.1074/jbc.C300300200Search in Google Scholar

34 Basu J, Williams B, Li Z, Williams E, Goldberg M. Depletion of a Drosophila homolog of yeast Sup35p disrupts spindle assembly, chromosome segregation, and cytokinesis during male meiosis. Cell Motil Cytoskel 1998; 39: 286–302. 10.1002/(SICI)1097-0169(1998)39:4<286::AID-CM4>3.0.CO;2-1Search in Google Scholar

35 Valouev I, Kushnirov V, Ter-Avanesyan D. Yeast polypeptide chain release factors eRF1 and eRF3 are involved in cytoskeleton organization and cell cycle regulation. Cell Motil Cytoskel 2002; 52: 161–73. 10.1002/cm.10040Search in Google Scholar

36 Kikushi Y, Shimatake H, Kikuchi A. A yeast gene required for the G1-to-S transition encodes a protein containing an A-kinase target site and GTPase domain. EMBO J 1988; 7: 1175–81. 10.1002/j.1460-2075.1988.tb02928.xSearch in Google Scholar

37 Hoshino S, Miyazawa H, Enomoto T, Hanaoka F, Kikuchi Y, Kikuchi A, et al. A human homologue of the yeast GST1 gene codes for a GTP-binding protein and is expressed in a proliferation-dependent manner in mammalian cells. EMBO J 1989; 8: 3807–14. 10.1002/j.1460-2075.1989.tb08558.xSearch in Google Scholar

38 Hoshino S, Imai M, Mizutani M, Kikuchi Y, Hanaoka F, Ui M, et al. Molecular cloning of a novel member of the eukaryotic polypeptide chain-releasing factors (eRF). J Biol Chem 1998; 273: 22254–59. 10.1074/jbc.273.35.22254Search in Google Scholar

39 Hegde , R, Srinivasula S, Datta P, Madesh M, Wassell R, Zhang Z, et al. The polypeptide chain releasing factor GSPT1/eRF3 is proteolytically processed into an IAP-binding protein. J Biol Chem 2003; 278: 38699–706. 10.1074/jbc.M303179200Search in Google Scholar

40 Livak K, Schmittgen T. Analysis of relative gene expression data using real-time quantitative PCR and the 2 −ΔΔCT method. Methods 2001; 25: 402–8. 10.1006/meth.2001.1262Search in Google Scholar

41 Lallemand F, Courilleau D, Sabbah M, Redeuilh G, Mester J. Direct inhibition of the expression of cyclin D1 gene by sodium butyrate. Biochem Biophys Res Commun 1996; 229: 163–9. 10.1006/bbrc.1996.1774Search in Google Scholar

42 Takai N, Desmond JC, Kumagai T, Gui D, Said JW, Whittaker S, et al. Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res 2004; 10: 1141–9. 10.1158/1078-0432.CCR-03-0100Search in Google Scholar

43 Pellizaro C, Coradini D, Daniotti A, Abolafio G, Daidone MG. Modulation of cell cycle-related protein expression by sodium butyrate in human non-small cell lung cancer cell lines. Int J Cancer 2001; 91: 654–7. 10.1002/1097-0215(200002)9999:9999<::AID-IJC1117>3.0.CO;2-ISearch in Google Scholar

44 Hitomi T, Matsuzaki Y, Yokota T, Takaoka Y, Sakai T. p15 ink4b in HDAC inhibitor-induced growth arrest. FEBS Lett 2003; 554: 347–50. 10.1016/S0014-5793(03)01186-4Search in Google Scholar

45 Nakano K, Mizuno T, Sowa Y, Orita T, Yoshino T, Okuyama Y, et al. Butyrate activates the Waf1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line. J Biol Chem 1997; 277: 22199–206. 10.1074/jbc.272.35.22199Search in Google Scholar

46 Meric F, Hunt KK. Translation initiation in cancer: a novel target for therapy. Mol Cancer Ther 2002; 1: 971–9. Search in Google Scholar

47 Dua K, Williams TM, Beretta L. Translational control of the proteome: relevance to cancer. Proteomics 2001; 1: 1191–9. 10.1002/1615-9861(200110)1:10<1191::AID-PROT1191>3.0.CO;2-8Search in Google Scholar

48 Rajasekhar VK, Holland EC. Postgenomic global analysis of translational control induced by oncogenic signaling. Oncogene 2004; 23: 3248–64. 10.1038/sj.onc.1207546Search in Google Scholar

49 Le Goff X, Philippe M, Jean-Jean O. Overexpression of human release factor 1 alone has an antisuppressor effect in human cell. Mol Cell Biol 1997; 6: 3164–72. 10.1128/MCB.17.6.3164Search in Google Scholar PubMed PubMed Central

50 Kato MV, Sato H, Nagayoshi M, Ikawa Y. Upregulation of the elongation factor-1α gene by p53 in association with death of an erytroleukemic cell line. Blood 1997; 4: 1373–8. 10.1182/blood.V90.4.1373Search in Google Scholar

51 Kim MS, Kwon HJ, Lee YM, Baek JH, Jang JE, Lee SW, et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 2001; 7: 437–43. 10.1038/86507Search in Google Scholar PubMed